The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative

Alzheimer's and Dementia

Volumn 10, Issue 6, 2014, Pages 808-817

  Molinuevo, José Luis ^a,b   Blennow, Kaj ^c   Dubois, Bruno ^d   Engelborghs, Sebastiaan ^e,f   Lewczuk, Piotr ^g   Perret Liaudet, Armand ^h   Teunissen, Charlotte E ⁱ   Parnetti, Lucilla ^j  

^a HOSPITAL CLÍNIC   (Spain)

^b Barcelonaeta Brain Research Center   (Spain)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e ZNA Hospital Network Antwerp   (Belgium)

^f UNIVERSITY OF ANTWERP   (Belgium)

^g UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^h UNIVERSITÉ LYON 1   (France)

ⁱ VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^j UNIVERSITY OF PERUGIA   (Italy)

more..

Author keywords

Alzheimer's disease; Amyloid b peptides; Biomarkers; Cerebrospinal fluid; Standardization; Tau

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; TAU PROTEIN; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); PEPTIDE FRAGMENT;

AGED; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; CLINICAL PRACTICE; CONSENSUS; CONTROLLED STUDY; DEMENTIA; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE CLASSIFICATION; HUMAN; LUMBAR PUNCTURE; MOLECULAR DIAGNOSIS; NEUROPATHOLOGY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; STANDARDIZATION; DIFFERENTIAL DIAGNOSIS; FEMALE; MALE; MILD COGNITIVE IMPAIRMENT; STANDARD;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOLOGICAL MARKERS; CONSENSUS; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; MALE; MILD COGNITIVE IMPAIRMENT; PEPTIDE FRAGMENTS; REFERENCE STANDARDS; TAU PROTEINS;

EID: 84927178751     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2014.03.003     Document Type: Review

References (79)

1. R.A. Sperling, P.S. Aisen, L.A. Beckett, D.A. Bennett, S. Craft, and A.M. Fagan Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement 7 2011 280 292
2. M.S. Albert, S.T. DeKosky, D. Dickson, B. Dubois, H.H. Feldman, and N.C. Fox The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement 7 2011 270 279
3. G.M. McKhann, D.S. Knopman, H. Chertkow, B.T. Hyman, C.R. Jack Jr., and C.H. Kawas The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging and the Alzheimer's Association workgroup Alzheimers Dement 7 2011 263 269
4. R.A. Fishman Cerebrospinal fluid in diseases of the nervous system 2nd edn. 1992 WB Saunders Philadelphia
5. E.R. Peskind, R. Riekse, J.F. Quinn, J. Kaye, C.M. Clark, and M.R. Farlow Safety and acceptability of the research lumbar puncture Alzheimer Dis Assoc Disord 19 2005 220 225
6. A.M. Fagan, and R.J. Perrin Upcoming candidate cerebrospinal fluid biomarkers of Alzheimer's disease Biomark Med 6 2012 455 476
7. H. Hampel, K. Bürger, S.J. Teipel, A.L. Bokde, H. Zetterberg, and K. Blennow Core candidate neurochemical and imaging biomarkers of Alzheimer's disease Alzheimers Dement 4 2008 38 48
8. O. Hansson, H. Zetterberg, P. Buchhave, E. Londos, K. Blennow, and L. Minthon Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study Lancet Neurol 5 2006 228 234
9. N. Mattsson, H. Zetterberg, O. Hansson, N. Andreasen, L. Parnetti, and M. Jonsson CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment JAMA 302 2009 385 393
10. X. Da, J.B. Toledo, J. Zee, D.A. Wolk, S.X. Xie, and Y. Ou Integration and relative value of biomarkers for prediction of MCI to AD progression: Spatial patterns of brain atrophy, cognitive scores, APOE genotype and CSF biomarkers Neuroimage Clin 4 2013 164 173
11. B.C. Dickerson, D.A. Wolk, and Alzheimer's Disease Neuroimaging Initiative Biomarker-based prediction of progression in MCI: comparison of AD signature and hippocampal volume with spinal fluid amyloid-β and tau Front Aging Neurosci 5 2013 55
12. H. Zetterberg, K. Tullhög, O. Hansson, L. Minthon, E. Londos, and K. Blennow Low incidence of post-lumbar puncture headache in 1,089 consecutive memory clinic patients Eur Neurol 63 2010 326 330
13. K. Blennow, A. Wallin, and O. Häger Low frequency of post-lumbar puncture headache in demented patients Acta Neurol Scand 88 1993 221 223
14. D.S. Knopman, S.T. DeKosky, J.L. Cummings, H. Chui, J. Corey-Bloom, and N. Relkin Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology Neurology 56 2001 1143 1153
15. M. Ewers, M. Brendel, A. Rizk-Jackson, A. Rominger, P. Bartenstein, and N. Schuff Reduced FDG-PET brain metabolism and executive function predict clinical progression in elderly healthy subjects Neuroimage Clin 4 2013 45 52
16. P.T. Trzepacz, P. Yu, J. Sun, K. Schuh, M. Case, and M.M. Witte Comparison of neuroimaging modalities for the prediction of conversion from mild cognitive impairment to Alzheimer's dementia Neurobiol Aging 35 2014 143 151
17. R. Takahashi, K. Ishii, M. Senda, K. Ito, K. Ishii, and T. Kato Equal sensitivity of early and late scans after injection of FDG for the detection of Alzheimer pattern: an analysis of 3D PET data from J-ADNI, a multi-center study Ann Nucl Med 27 2013 452 459
18. J.C. Morris, and A.L. Price Pathologic correlates of non-demented aging, mild cognitive impairment, and early-stage Alzheimer's disease J Mol Neurosci 17 2001 101 118
19. R. Tarawneh, and D.M. Holtzman Critical issues for successful immunotherapy in Alzheimer's disease: development of biomarkers and methods for early detection and intervention CNS Neurol Disord Drug Targets 8 2009 144 159
20. A. Perret-Liaudet, A. Dorey, Y. Tholance, B. Dumont, and I. Quadrio Pre-analytical and analytical critical factors influencing the high variability of the concentrations levels of Alzheimer disease biomarkers in cerebral spinal fluid Understanding Alzheimer's disease 2013 Intech p177 p192 Chapter 8
21. H. Vanderstichele, M. Bibl, S. Engelborghs, N. Le Bastard, P. Lewczuk, and J.L. Molinuevo Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative Alzheimers Dement 8 2012 65 73
22. G. McKhann, D. Drachman, M. Folstein, R. Katzman, D. Price, and E.M. Stadlan Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease Neurology 34 1984 939 944
23. T.G. Beach, S.E. Monsell, L.E. Phillips, and W. Kukull Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010 J Neuropathol Exp Neurol 71 2012 266 273
24. M. Balasa, E. Gelpi, A. Antonell, M.J. Rey, R. Sánchez-Valle, and J.L. Molinuevo Clinical features and APOE genotype of pathologically proven early-onset Alzheimer disease Neurology 76 2011 1720 1725
25. E. Westman, J.S. Muehlboeck, and A. Simmons Combining MRI and CSF measures for classification of Alzheimer's disease and prediction of mild cognitive impairment conversion Neuroimage 62 2012 229 238
26. H. Hampel, S. Lista, S.J. Teipel, F. Garaci, R. Nisticò, and K. Blennow Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: A long-range point of view beyond 2020 Biochem Pharmacol 88 2014 426 449
27. N. Le Bastard, J.J. Martin, E. Vanmechelen, H. Vanderstichele, P.P. De Deyn, and S. Engelborghs Added diagnostic value of CSF biomarkers in differential dementia diagnosis Neurobiol Aging 31 2010 1867 1876
28. F. Tabaraud, J.P. Leman, A.M. Milor, J.M. Roussie, G. Barrière, and M. Tartary Alzheimer CSF biomarkers in routine clinical setting Acta Neurol Scand 125 2012 416 423
29. S. Engelborghs Clinical indications for analysis of Alzheimer's disease CSF biomarkers Rev Neurol (Paris) 169 2013 709 714
30. S. Slaets, N. Le Bastard, J. Theuns, K. Sleegers, A. Verstraeten, and E. De Leenheir Amyloid pathology influences aβ1-42 cerebrospinal fluid levels in dementia with lewy bodies J Alzheimers Dis 35 2013 137 146
31. C.J. Galton, K. Patterson, J.H. Xuereb, and J.R. Hodges Atypical and typical presentations of Alzheimer's disease: a clinical, neuropsychological, neuroimaging and pathological study of 13 cases Brain 123 2000 484 498
32. K.A. Jellinger, and J. Attems Prevalence of dementia disorders in the oldest-old: an autopsy study Acta Neuropathol 119 2010 421 433
33. A. Carotenuto, R. Rea, L. Colucci, A.R. Ziello, I. Molino, and S. Carpi Late and early onset dementia: what is the role of vascular factors? A retrospective study J Neurol Sci 322 2012 170 175
34. B. Dubois, H.H. Feldman, C. Jacova, H. Hampel, J.L. Molinuevo, and K. Blennow Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria Lancet Neurol 13 2014 614 629
35. 181P levels J Alzheimers Dis 36 2013 759 767
36. P.E. Spies, D. Slats, J.M. Sjögren, B.P. Kremer, F.R. Verhey, and M.G. Rikkert The cerebrospinal fluid amyloid beta 42/40 ratio in the differentiation of Alzheimer's disease from non-Alzheimer's dementia Curr Alzheimer Res 7 2010 470 476
37. J. Wiltfang, H. Esselmann, M. Bibl, M. Hüll, H. Hampel, and H. Kessler Amyloid beta peptide ratio 42/40 but not A beta 42 correlates with phospho-Tau in patients with low- and high-CSF A beta 40 load J Neurochem 101 2007 1053 1059
38. Dorey A, Tholance Y, Dauphinot V. Interet du ratio AB42/AB40 dans le diagnostic de la maladie d'Alzheimer. 11èmes journées francophones sur la Maladie d'Alzheimer et apparentées. 24 May 2012 Toulouse.
39. N.S. Schoonenboom, F.E. Reesink, N.A. Verwey, M.I. Kester, C.E. Teunissen, and P.M. van de Ven Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort Neurology 78 2012 47 54
40. S. Jayaratnam, A.K. Khoo, and D. Basic Rapidly progressive Alzheimer's disease and elevated 14-3-3 proteins in cerebrospinal fluid Age Ageing 37 2008 467 469
41. G. Chohan, C. Pennington, J.M. Mackenzie, M. Andrews, D. Everington, and R.G. Will The role of cerebrospinal fluid 14-3-3 and other proteins in the diagnosis of sporadic Creutzfeldt-Jakob disease in the UK: a 10-year review J Neurol Neurosurg Psychiatry 81 2010 1243 1248
42. K. Stoeck, P. Sanchez-Juan, J. Gawinecka, A. Green, A. Ladogana, and M. Pocchiari Cerebrospinal fluid biomarker supported diagnosis of Creutzfeldt-Jakob disease and rapid dementias: a longitudinal multicentre study over 10 years Brain 135 2012 3051 3061
43. N. Mattsson, U. Andreasson, S. Persson, M.C. Carrillo, S. Collins, S. Chalbot, and N. Cutler CSF biomarker variability in the Alzheimer's Association quality control program Alzheimers Dement 9 2013 251 261
44. J. Hort, A. Bartos, T. Pirttilä, and P. Scheltens Use of cerebrospinal fluid biomarkers in diagnosis of dementia across Europe Eur J Neurol 17 2010 90 96
45. J.W. Bartlett, C. Frost, N. Mattsson, T. Skillbäck, K. Blennow, and H. Zetterberg Determining cut-points for Alzheimer's disease biomarkers: statistical issues, methods and challenges Biomark Med 6 2012 391 400
46. J.L. Price, and J.C. Morris Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease Ann Neurol 45 1999 358 368
47. P. Buchhave, L. Minthon, H. Zetterberg, A.K. Wallin, K. Blennow, and O. Hansson Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia Arch Gen Psychiatry 69 2012 98 106
48. S. Lehmann, S. Schraen, I. Quadrio, C. Paquet, S. Bombois, and C. Delaby Impact of harmonization of collection tubes on Alzheimer's disease diagnosis Alzheimers Dement 2013 Oct 23. [Epub ahead of print]
49. N. Mattsson, U. Andreasson, S. Persson, H. Arai, S.D. Batish, and S. Bernardini The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers Alzheimers Dement 7 2011 386 395
50. S.M. Landau, M. Lu, A.D. Joshi, M. Pontecorvo, M.A. Mintun, and J.Q. Trojanowski Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β-amyloid Ann Neurol 74 2013 826 836
51. J.B. Toledo, S.X. Xie, J.Q. Trojanowski, and L.M. Shaw Longitudinal change in CSF tau and Aβ biomarkers for up to 48 months in ADNI Acta Neuropathol 126 2013 659 670
52. P. Lewczuk, R. Zimmermann, J. Wiltfang, and J. Kornhuber Neurochemical dementia diagnostics: a simple algorithm for interpretation of the CSF biomarkers J Neural Transm 116 2009 1163 1167
53. J.L. Molinuevo, J.D. Gispert, B. Dubois, M.T. Heneka, A. Lleo, and S. Engelborghs The AD-CSF-Index Discriminates Alzheimer's Disease Patients from Healthy Controls: A Validation Study J Alzheimers Dis 36 2013 67 77
54. F. Hulstaert, K. Blennow, A. Ivanoiu, H.C. Schoonderwaldt, M. Riemenschneider, and P.P. De Deyn Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF Neurology 52 1999 1555 1562
55. S. Engelborghs, K. De Vreese, T. Van de Casteele, H. Vanderstichele, B. Van Everbroeck, and P. Cras Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia Neurobiol Aging 29 2008 1143 1159
56. P.J. Visser, F. Verhey, D.L. Knol, P. Scheltens, L.O. Wahlund, and Y. Freund-Levi Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study Lancet Neurol 8 2009 619 627
57. M. Sjögren, H. Vanderstichele, H. Agren, O. Zachrisson, M. Edsbagge, and C. Wikkelsø Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values Clin Chem 47 2001 1776 1781
58. N. Mattsson, E. Rosén, O. Hansson, N. Andreasen, L. Parnetti, and M. Jonsson Age and diagnostic performance of Alzheimer disease CSF biomarkers Neurology 78 2012 468 476
59. G. De Meyer, F. Shapiro, H. Vanderstichele, E. Vanmechelen, S. Engelborghs, and P.P. De Deyn Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people Arch Neurol 67 2010 949 956
60. K.L. Howard, and C.M. Filley Advances in genetic testing for Alzheimer's disease Rev Neurol Dis 6 2009 26 32
61. J.A. Prince, H. Zetterberg, N. Andreasen, J. Marcusson, and K. Blennow APOE epsilon4 allele is associated with reduced cerebrospinal fluid levels of Abeta42 Neurology 62 2004 2116 2118
62. U. Andreasson, R. Lautner, J.M. Schott, N. Mattsson, O. Hansson, and S.K. Herukka CSF biomarkers for Alzheimer's pathology and the effect size of APOE ε4 Mol Psychiatry 19 2014 148 149
63. B. Dubois, H.H. Feldman, C. Jacova, J.L. Cummings, S.T. Dekosky, and P. Barberger-Gateau Revising the definition of Alzheimer's disease: a new lexicon Lancet Neurol 9 2010 1118 1127
64. B.T. Hyman, C.H. Phelps, T.G. Beach, E.H. Bigio, N.J. Cairns, and M.C. Carrillo National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease Alzheimers Dement 8 2012 1 13 10.1016/j.jalz.2011.10.007
65. K. Blennow, and H. Hampel CSF markers for incipient Alzheimer's disease Lancet Neurol 2 2003 605 613
66. K. Blennow, M.J. de Leon, and H. Zetterberg Alzheimer's disease Lancet 368 2006 387 403
67. K. Blennow, and H. Zetterberg Is it time for biomarker-based diagnostic criteria for prodromal Alzheimer's disease? Alzheimers Res Ther 2 2010 8
68. S.M. Landau, D. Harvey, C.M. Madison, E.M. Reiman, N.L. Foster, and P.S. Aisen Comparing predictors of conversion and decline in mild cognitive impairment Neurology 75 2010 230 238
69. A. Brück, J.R. Virta, J. Koivunen, J. Koikkalainen, N.M. Scheinin, and H. Helenius [11C]PIB, [18F]FDG and MR imaging in patients with mild cognitive impairment Eur J Nucl Med Mol Imaging 40 2013 1567 1572
70. J. Arbizu, E. Prieto, P. Martínez-Lage, J.M. Martí-Climent, M. García-Granero, and I. Lamet Automated analysis of FDG PET as a tool for single-subject probabilistic prediction and detection of Alzheimer's disease dementia Eur J Nucl Med Mol Imaging 40 2013 1394 1405
71. H. Zetterberg, and K. Blennow Cerebrospinal fluid biomarkers for Alzheimer's disease: more to come? J Alzheimers Dis 33 2013 S361 S369
72. J.L. Molinuevo, and L. Rami Applying the IWG research criteria in clinical practice: feasibility and ethical issues Med Clin North Am 97 2013 477 484
73. [No authors listed] Consensus report of the Working Group on: "Molecular and Biochemical Markers of Alzheimer's Disease". The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group Neurobiol Aging 19 1998 109 116
74. D. Strozyk, K. Blennow, L.R. White, and L.J. Launer CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study Neurology 60 2003 652 656
75. K. Buerger, M. Ewers, T. Pirttilä, R. Zinkowski, I. Alafuzoff, and S.J. Teipel CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease Brain 129 2006 3035 3041
76. S. Engelborghs, K. Sleegers, P. Cras, N. Brouwers, S. Serneels, and E. De Leenheir No association of CSF biomarkers with APOEepsilon4, plaque and tangle burden in definite Alzheimer's disease Brain 130 2007 2320 2326
77. C.R. Jack Jr., M.S. Albert, D.S. Knopman, G.M. McKhann, R.A. Sperling, and M.C. Carrillo Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement 7 2011 257 262
78. J.E. Meredith Jr., S. Sankaranarayanan, V. Guss, A.J. Lanzetti, F. Berisha, and R.J. Neely Characterization of novel CSF Tau and ptau biomarkers for Alzheimer's disease PLoS One 8 2013 e76523
79. T. Oe, B.L. Ackermann, K. Inoue, M.J. Berna, C.O. Garner, and V. Gelfanova Quantitative analysis of amyloid beta peptides in cerebrospinal fluid of Alzheimer's disease patients by immunoaffinity purification and stable isotope dilution liquid chromatography/negative electrospray ionization tandem mass spectrometry Rapid Commun Mass Spectrom 20 2006 3723 3735